Adipose – Derived Stem Cells for Future Regenerative System Medicine

Yani Lina[1]*, and Andi Wijaya[1,2]

[1]Post Graduate Program in Clinical Biochemistry, Hasanuddin University, Jl. Perintis Kemerdekaan Km.10. Makassar, Indonesia
[2]Prodia Clinical Laboratory, Jl. Cisangkuy No.2, Bandung, Indonesia
*Correspondence: Prodia StemCell Indonesia, Jl. Kramat VII No.11, Jakarta, Indonesia
e-mail: yani_lina1979@yahoo.com

Abstract

BACKGROUND: The potential use of stem cell-based therapies for repair and regeneration of various tissues and organs offers a paradigm shift that may provide alternative therapeutic solutions for a number of diseases. Despite these advances, the availability of stem cells remains a challenge for both scientists and clinicians in pursuing regenerative medicine.

CONTENT: Subcutaneous human adipose tissue is an abundant and accessible cell source for applications in tissue engineering and regenerative medicine. Routinely, the adipose tissue is digested with collagenase or related lytic enzymes to release a heterogeneous population for stromal vascular fraction (SVF) cells. The SVF cells can be used directly or can be cultured in plastic ware for selection and expansion of an adherent population known as adipose-derived stromal/stem cells (ASCs). Their potential in the ability to differentiate into adipogenic, osteogenic, chondrogenic and other mesenchymal lineages, as well in their other clinically useful properties, includes stimulation of angiogenesis and suppression of inflammation.

Abstrak

LATAR BELAKANG: Potensi penggunaan terapi berbasis *stem cell* untuk memperbaiki dan regenerasi berbagai jaringan dan organ memberikan paradigma baru dalam penyediaan alternatif terapi berbagai jenis penyakit. Akan tetapi di balik semua itu, ketersediaan *stem cell* tetap menjadi tantangan bagi ilmuwan maupun klinisi di dalam *regenerative medicine*.

ISI: Jaringan adiposa subkutan meruapakn sumber sel yang berlimpah untuk diaplikasikan dalam *tissue engineering* dan *regenerative medicine*. Jaringan adipose ditambahkan *collagenase* atau *lytic enzymes* untuk melepaskan populasi *stromal vascular fraction* (SVF) *cells*. *SVF cells* dapat digunakan langsung atau dapat dikultur untuk selanjutnya dilakukan seleksi dan ekspansi dari *adherent population* yang diketahui sebagai *adipose-derived stromal/stem cells* (ASCs). ASC memiliki potensi untuk berdiferensiasi menjadi *lineage adipogenic, osteogenic, chondrogenic* dan *lineage mesenchymal* lainnya, serta penggunaannya secara klinis, meliputi stimulasi angiogenesis dan menekan inflamasi.

SUMMARY: Adipose tissue is now recognized as an accessible, abundant and reliable site for the isolation of adult stem cells suitable for the application of tissue engineering and regenerative medicine applications. The past decade has witnessed an explosion of preclinical data relating to the isolation, characterization, cryopreservation, differentiation, and transplantation of freshly isolated stromal vascular fraction cells and adherent, culture-expanded, adipose-derived stromal/stem cells *in vitro* and in animal models.

KEYWORDS: Adipose tissue, adult stem cells, regenerative medicine, mesenchymal stem cells

Indones Biomed J 2012; 4 (2): 59-72

RINGKASAN: Jaringan adiposa dikenal sebagai jaringan yang mudah diakses, berlimpah dan terpercaya untuk isolasi *adult stem cell* yang cocok untuk aplikasi *tissue engineering* dan *regenerative medicine*. Studi terdahulu telah menunjukkan data preklinis terkait dengan isolasi, karakterisasi, *cryopreservation*, diferensiasi dan transplantasi *freshly isolated stromal vascular fraction cells* dan *adherent, culture-expanded, adipose-derived stromal/stem cells* baik *in vitro* maupun pada *animal models*.

KEYWORDS: *Adipose tissue, adult stem cells, regenerative medicine, mesenchymal stem cells*

Indones Biomed J 2012; 4 (2): 59-72

Introduction

The therapeutic potential of multilineage stem cells is enormous for their possible applications in tissue engineering and gene therapy (1). Essentially, there are only two types of stem cells: the embryonic stem cell (ES cell) and adult stem cell. The ES cell, as its name implies, is derived from embryo, or more specifically, from the blastocyst's inner cell mass. In contrast, the adult stem cell is derived from postnatal tissues and can include fetal-derived stem cells and umbilical cord blood stem cells. Over the last 10 years, giant strides have been made worldwide in the field of adult stem cell. In 2002, researchers at UCLA published a manuscript in Molecular Biology of the Cell describing a novel adult stem cell population isolated from adipose tissue – the adipose-derived stem cell (ASC). Since that time, the ASC has become to be one of the most popular adult stem cell populations currently being used in the stem cell field (2).

With the increased incidence of obesity worldwide, subcutaneous adipose tissue is abundant and readily accessible. Approximately 400,000 liposuction surgeries are performed in the United States each year. One procedure of the surgery may yield from 100 mL to > 3 L of lipoaspirate tissue; this material is routinely discarded (3,4).

Similar to other rapidly developing fields, a variety of names have been used to refer to the plastic adherent cell populations isolated from collagenase digests of adipose tissue: adipose-derived stem/stromal cells (ASCs), adipose-derived adult stem (ADAS) cells, adipose-derived adult stromal cells, adipose-derived stromal cells (ADSCs), adipose stromal cells (ASCs), adipose mesenchymal stem cells (AdMSCs), lipoblast, pericyte, preadipocyte, and processed lipoaspirate (PLA) cells. To prevent confusion that may arise from the several different names, the International Fat Applied Technology Society has reached to a globally-agreed consensus to adopt the term "adipose-derived stem cells (ASCs)" to refer to the isolated, plastic-adherent, multipotent cell population (5).

The possible feature of ASC being pluripotent cells may obviously lead to a turning point in the stem cell field. Today, the strongly proposed uses of ASCs in tissue repair/regeneration are quite impressive. Hot areas of research in this field include ischemia revascularization, cardiovascular tissue regeneration, bone/cartilage repair, and urinary tract reconstruction (2). Liver injury repair may also be possible by transplantation of rat ASCs, decreasing key liver enzyme levels and increasing serum albumin (6). Even diabetes may be a target for ASC therapy with murine ASCs that can reduce hyperglycemia in diabetic mice (7). Most recently, researchers have begun to explore the potential uses of 'reprogrammed" ASCs as iPS (induced pluripotent stem) cells and suggested that the ASC may be easier to reprogram than the fibroblast (8).

There is a growing body of experimental evidence from both *in vitro* and *in vivo* studies demonstrating the multipotentiality of ASCs from adipose tissue isolated from human and other species. These include the adipocyte, the chondrocyte, hematopoietic supporting,

hepatocyte, neuronal-like, osteoblast, pancreatic, and skeletal myocyte pathways (5,9-30). There is no other human tissue as expendable as the adipose tissue, making it relatively easy to isolate adequate number of ASCs for possible human therapies. With this fact, together with the early clinical uses of ASCs with no adverse effects being reported, it seems only a matter of time before more and more clinical applications of ASCs are reported (2).

Adipose Tissue, Its Cellular Components

Historically, adipose tissue (AT) has been thought to play a passive metabolic role, acting solely as an energy storage reservoir (31). This view has changed, and now adipose tissue is considered an important endocrine organ that provides plastic properties (32,33). Recently, adipose tissue has been also reported as an important reservoir of stem cells with possible practical uses in medicine (34).

Three functionally different types of adipose tissues are classically described in mammals, namely Brown Adipose Tissue (BAT), White Adipose Tissue (WAT) and Bone Marrow Adipose Tissue (BMAT) (35-37). Brown and white adipocytes display both lipolytic and lipogenic activities, but the main role of white adipocytes is to store and mobilize energy as triglycerides, while brown adipocytes are specialized in energy dissipation as heat. Bone marrow adipocytes can contribute to haematopoiesis and osteoblastogenesis by acting as metabolic stores but also via their paracrine activities (38).

Excessive AT development is thought to be the result of both adipocyte hypertrophy and apparent hyperplasia (39-43). As adipocytes are terminally differentiated cells, and as such are considered incapable of division (44,45), the apparent increase in adipocyte number is thought to originate from adipogenesis (the proliferation/ differentiation of adipocyte progenitor cells named preadipocytes). Thus, the expansion of adipose mass requires the presence of adipocyte precursor cells located in the stroma vascular fraction of AT and the presence of which could also contribute to AT normal cell turnover during adulthood as recently suggested (46). The search for the origin of adipocyte progenitors revealed that AT hosts a population of multipotent progenitors called adipose-derived stromal cells (ASCs) (5,7). These progenitors can give rise to osteoblasts, chondrocytes and adipocytes (5). They also participate in and/or support

angiogenesis or vascular repair in ischemic limbs (47-49) and have immuno-modulatory properties both *in vitro* and *in vivo* (50-51).

AT is composed mainly of fat cells organized into lobules (52). It is a highly complex tissue consisting of mature adipocytes, which constitutes more than 90% of the tissue volume, and a SVF, which includes preadipocytes, fibroblasts, vascular smooth muscle cells, endothelial cells, resident monocytes/macrophages, lymphocytes, and ASCs (53,54). ASCs harvested from superficial abdominal regions are significantly more resistant to apoptosis than ASC harvested from the upper arm, medial thigh, trochanteric part, and superficial deep abdominal depots (55). The density of stem cell reserves varies within adipose tissue and is a function of location, type and species (e.g. human vs murine). In white adipose tissue, for example, ASC yields are greater in subcutaneous depots than in visceral fat, with the highest concentrations being in arm adipose tissue depots and the greatest plasticity in ASCs isolated from inguinal adipose tissue depots (56).

Isolated from the SVF of AT, ASCs bear a strong resemblance to bone marrow stem cells (BMSC) as demonstrated by their expression of common cell surface markers, their similar gene expression profiles, and their similar differentiation potentials (5,57,58). Unlike BMSC, however, ASC can be obtained in large quantities at low risks (59). In addition to being more abundant and easily accessible, the adipose tissue yields far more stem cells than bone marrow on a per gram basis (5,000 vs 100-1,000) (60). Therefore, it is reasonable to expect that ASC will become the preferred choice of adult stem cells for future clinical applications.

ASCs and Stromal Vascular Fraction

Subcutaneous fat is an abundant and accessible source of both uncultured/heterogeneous SVF cells and cultured/ relatively homogeneous ASCs (61). The molecular phenotype of ASC has only recently been clarified (62), following many years of referring to any cultured SVF cells as ASC. Freshly isolated SVF contains a mixture of cells, which not only includes ASC but also contains endothelial cells, smooth muscle cells, pericytes, fibroblasts, and circulating cell types such as leukocytes, hematopoietic stem cells, or endothelial progenitor cells (63,64). Through collagenase digestion, a heterogeneous cell mixture containing all cell types, except adipocytes, can be extracted from adipose tissue (or liposuction

aspirates) as a cell pellet. Adipocytes are disrupted into oil during the process and discarded as floating tissue and oil after centrifugation. The sedimented cell fraction is called the stromal vascular fraction (SVF) and is basically stromal cells along with vascular endothelial and mural cells (52). Study identified freshly isolated ASCs as CD31⁻ CD34⁺CD45⁻CD90⁺CD105⁻CD146–cells, but they become CD105⁺ when plated (65). Nucleate cells contained in the SVF obtained from lipoaspirates are composed of 37% leukocytes (CD45⁺), 35% ASCs (CD31⁻CD34⁺CD45⁻), 15% endothelial cells (CD31⁺CD34⁺CD45⁻) and other cells (CD31⁻CD34⁻CD45-), although the percentage of blood-derived cells strongly depends on individual hemorrhage volume (66). ASCs can be extracted from both the floating fatty portion and fluid portion of liposuction aspirates; however, the fluid portion contains much fewer adipose-derived cells and may more blood-derived cells. ASCs can be used clinically without cell expansion if harvested from a large volume of lipoaspirates because a sufficient number of cells can be obtained; 0.1-1 billion nucleate cells can be obtained from 200 mL of aspirated fat tissue and at least 10% of these are ASCs. The use of freshly isolated cells likely leads to higher safety and efficacy in treatments compared with cells expanded by culture (52).

The fact that stem cells yields are greater from AT than from other stem cell reservoirs is another significant factor in their suitability for use in regenerative medicine. Routinely, 1×10^7 adipose stromal/stem cells have been isolated from 300 mL of lipoaspirate, with greater than 95% purity (67). In other words, the average frequency of ASC in processed lipoaspirate is 2% of nucleated cells, and the yield of ASCs is approximately 5,000 fibroblast colony-forming units (CFU-F) per gram of adipose tissue, compared with estimates of approximately 100-1,000 CFU-F per milliliter of bone marrow (60). Several groups have demonstrated that mesenchymal cells within the SVF of subcutaneous adipose tissue display multilineage developmental plasticity. These cells have alternatively been referred to as processed lipoaspirate cells (PLA), adipose-derived stem cells, and adipose-derived mesenchymal progenitor cells. It is also likely that cells previously considered preadipocytes are essentially the same population (9,68).

Mesenchymal stem cells seem to be an ideal population of stem cells for practical regenerative medicine, because they are not subjected to the same restrictions. In particular, large number of ASCs can be easily harvested from adipose tissue. Furthermore, recent basic research and preclinical studies have revealed that the use of ASCs in regenerative medicine is not limited to mesodermal tissue but extends to both ectodermal and endodermal tissues and organs

although ASCs originate from mesodermal lineages (69). The proliferation capacity of ASCs seems to be greater than that of bone marrow-derived mesenchymal stem cells. Previous reports have shown that the doubling times of ASC during the logarithmic phase of growth range from 40 to 120 hours (14,70,71) are influenced by donor age, type (white or brown adipose tissue), the harvesting procedure, culture conditions, plating density and media formulations (63,72). The younger the donor, the greater the proliferation and cell adhesion of the ASCs, while cells gradually lose their proliferative capacity with passaging (71). Based on β-galactosidase activity, senescence in ASCs is similar to that in bone marrow-derived MSCs (70).

The proliferation of ASCs can be stimulated by a single growth factor such as fibroblast growth factor (FGF)-2, endothelial growth factor (EGF), insulin-like growth factor (IGF)-1 or TNF-α (72,73). FGF-2, in particular, is an effective growth-stimulating factor and is required for the long-term propagation and self-renewal of ASCs via the extracellular signal-related kinase (ERK) 1/2 signaling pathway (74). The proliferation of ASCs can also be stimulated by platelet-derived growth factor (PDGF) via Jun amino-terminal kinase (JNK) activation (75) and by oncostatin M via activation of the microtubule-associated protein kinase/ERK and the JAK3/STAT1 pathways (76). ASCs proliferation is also reported to be enhanced by multiple growth factors, which can include any of the single factors mentioned above supplemented by thrombin-activated platelet-rich plasma (77), human platelet lysate (78) and human thrombin (79).

As far as the differentiation into cells of the mesodermal lineages and regeneration of mesodermal tissues are concerned, ASCs can differentiate into adipogenic (80-82), osteogenic (83), chondrogenic (83-85), myogenic (30), cardiomyogenic (86-87), angiogenic (48,88), tenogenic (89), and periodontogenic lineages (90), and tissue regeneration studies with suitable scaffolds and growth factors in appropriate external environment have been carried out (91,92). It has been shown that ASCs can differentiate into endoderm lineage cells. Several reports have shown that ASCs have the potential to differentiate into hepatocytes as indicated by the presence of hepatocyte growth factor (HGF) and FGF-1 (93,94). In theory, ASCs could be used to reduce liver inflammation and treat liver fibrosis by differentiating directly into hepatocytes or by secreting factors such as angiogenic, anti-apoptotic, anti-inflammatory, and anti-fibrotic factors. In addition to hepatic differentiation, the exposure of ASCs to nicotinamide, activin-A, exendin-4, HGF, and pentagastrin resuted in the production of pancreatic-

Figure 1. The Process of ASC Clinical Usage (adapted with permission from John Wiley and Sons 2012)

like ASCs capable of insulin, glucagon and somatostatin secretion (28,95). The recent International Federation of Adipose Therapeutics and Science meeting in Dallas, Texas (October 22-24, 2010) demonstrated some of the many novel uses of lipoaspirate, SVF and ASC that are currently being investigated to solve clinical problems (96).

Cytokine Profile and Immunogenicity of ASCs

Adipose tissue serves as source of adipokines and cytokines with both local and systemic actions in health and disease (97). It has been shown that the beneficial impact on different organ/tissues within the human body may be due to soluble factors produced by ASCs rather than their differentiation capability toward different mature lineages (98). Analysis of the soluble factors released from human ASCs have revealed that cultured ASCs, at relatively early passages, secrete hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), transforming growth factor-β (TGF-β), insulin-like growth factor (IGF)-1, basic fibroblast growth factor (bFGF), granulocyte-macrophage colony stimulating factor, TNF-α, interleukin (IL)-6, IL-7, IL-8 and IL-11, adiponectin, angiotensin, cathepsin D, pentraxin, pregnancy zone protein, retinol-binding protein, and CXCL12 (48,97,99). Thus, it may be that when ASCs are transplanted into inflammatory or ischemic regions, they actively secrete these growth factors, thereby significantly promoting wound healing and tissue repair (69). Thus, ASCs display cytokine secretory properties similar to those reported for bone marrow-derived mesenchymal stem cells (MSCs) (97).

Multiple independent groups have examined the surface immunophenotype of ASCs isolated from human and other species (9,10,65,100-107). The expression profile changes as a function of time in passage and plastic adherence (63,106). After 2 or more successive passages in culture, the ASCs express characteristic adhesion and receptor molecules, surface enzymes, extracellular matrix and cytoskeletal proteins, and proteins associated with the stromal cell phenotype. Despite any differences in the isolation and culture procedures, the immunophenotype is relatively consistent between laboratories. Indeed, the surface immunophenotype of ASCs resembles that of bone marrow-derived mesenchymal stem or stromal cells (MSCs) (108) and skeletal muscle-derived cells (109). Direct comparison between human ASC and MSC immunophenotypes are > 90% identical (9). Analyses of the ASC and adipocyte proteome by mass spectrometry and other approaches have documented the identity of > 200 proteins in both the undifferentiated and adipose differentiated cells (110-116). The human ASC proteome shares features in common to that reported for fibroblasts, MSCs, and other lineages (111,117,118).

Freshly isolated SVF cells are a heterogeneous cell population that includes putative ASCs (CD31⁻, CD34⁺/, CD45⁻, CD90⁺, CD105⁻, and CD146⁻), endothelial (progenitor) cells (CD31⁺, CD34⁺, CD45⁻, CD90⁺, CD105, and CD146⁺), vascular smooth muscle cells or pericytes (CD31⁻, CD 34⁺/⁻, CD45⁻, CD90⁺, CD105⁻, and CD146⁺), and hematopoietic cells (CD45+) in uncultured conditions (119). Additionally, compared with ASCs from later passages, freshly isolated SVF cells and early passages ASCs express higher levels of CD117 (c-kit), human leukocyte antigen-DR (HLA-DR), and stem cell-associated markers such as CD34, along with lower levels of stromal cell markers such as CD13, CD29 (β1 integrin), CD44, CD63, CD73, CD90, CD105, and CD116 (63,65,68,103,119-132). While the consequences of the decrease in CD34 expression in later passage ASCs are not clear, there is al least one study demonstrating that CD34 expression can be maintained during 20 weeks of culture (65). As indicated, ASCs share many cell surface markers with pericytes and bone marrow-MSCs. Except for those mentioned above, the pericyte markers expressed by ASCs include smooth muscle β-actin, platelet-derived growth factor (PDGF) receptor-β, and neuro-glial proteoglycan 2 (121), while the markers shared by ASCs and MSCs include CD13, CD29, CD44, CD58 and CD166. Finally, Puissant *et al.* (50) have reported on the lack of HLA-DR expression and the immunosuppressive properties of human ASCs. Based on such findings, Fang et al published preliminary data showing that severe steroid-refractory acute graft-versus-host disease (GVHD) could be treated with human ASCs from HLA-mismatched donors (133).

Clinical Translation of ASCs

Adipose tissue is a source of freshly isolated, heterogeneous stromal vascular fraction cells and culture-expanded, adherent, and relatively homogeneous adipose stromal/stem cells. Both population display regenerative capcity in soft and hard tissue repair, ischemic insults and autoimmune diseases. While their major mechanism of action has been attributed to both direct lineage differentiation and/or paracrine factor release, current evidence favors a paracrine mechanism. Over 40 clinical trials using adipose-derived cells conducted in 15 countries have been registered with the NIH, the majority of which are Phase I or Phase I/II safety studies. Explorations into the regenerative potential of adipose-derived cells occur throughout the world (134). In Asia and Europe, regulatory approval has been granted for closed mechanical devices for adipose tissue processing and SVF cell isolation using collagenase digestion (135). The avaibility of these machines in operating rooms has facilitated the point-of-care delivery of SVF cells for investigators and clinicians in Asia and Europe. Clinical applications using adipose-derived cells are underway throughout Asia, Europe and North and South America. Some of these can be found on the NIH's website (136), where 55 studies are listed under the search term 'adipose stem cell' (as of 22 October 2011). Of these, 44 studies actually employ adipose-derived cells or tissues for regenerative applications (134).

There remains some dispute over the criteria defining an SVF cell or an ASC. While there is a general consensus that the SVF cells are a heterogeneous population, no specific ranges for each subpopulation have been agreed upon formally. The International Society for Stem Cell Therapy (ISCT) has provided guidelines for the definition of mesenchymal stromal cells (MSCs) based on their plastic adherent properties, immunophenotype (CD73⁺ CD90⁺ CD105⁺ CD11b/14⁻ CD19/CD73b⁻ CD34⁻ CD45⁻ HLA-DR-), and multipotent differentiation potential (adipogenic, chrondrogenic and osteogenic) (137). While some have attempted to apply these criteria to ASC, there is a reason to doubt their applicability because early passage ASCs are routinely CD34⁺ (106,119). Some have used the protein Pref1, first identified on murine 3T3-L1 preadipocytes, as a putative ASC marker (138). Others have reported the use of pericytic markers such as

platelet-derived growth factor receptor β and 3G5 (119, 139-142). The use of USP-based assays for each step in the ASC and SVF cell manufacturing process ensures the reproducibility and reliability of the final product. To date, most laboratories use several common steps to process cells from adipose tissue (84). These are : (a) washing; (b) enzymatic digestion/mechanical disruption; (c) centrifugal separation for isolation of SVF cells which can be used directly, cryopreserved, or (d) culture expanded for the generation of ASCs (5). Long-term storage will be critical to ensure a reliable supply and delivery of ASCs and SVF cells to point of care providers. The majority of published ASC and SVF cell cryopreservation procedures rely on the use of dimethyl sulfoxide (DMSO) as a cryoprotectant agent (CPA), often in combination with serum protein components (61). Both ASC and SVF cells have been used in preclinical models to treat acute and chronic diseases afflicting a range of tissues and organs (143).

Potential ASCs for Regenerative Medicine

Adipose depots are ubiquitously accessible in large quantities with a minimal invasive procedure (liposuction aspiration) and contain high amounts of ASCs, which is an essential prerequisite for stem cell-based therapies (144). It has been described that stem and progenitor cells in the primary isolates [(the so-called stroma-vascular fraction (SVF)] usually amount to up to 3%, and this is 2,500-fold more than the frequency of MSCs in bone marrow (up to 0.002%) (145). The plasticity of ASCs toward cells of the mesodermal lineage has been shown by their differentiation into chondrocytes, osteoblasts, adipocytes, and myocytes. Their potential to differentiate into lineages with nonmesodermal origin is even more exciting; ASCs are also able to differentiate into cells of ecto- and endodermal origin. Various *in vitro* and *in vivo* studies documented the induced differentiation into neural cells, hepatocytes, pancreatic islet cells, endothelial cells and epithelial cells (144).

a. Soft and Skeletal Tissue

Soft tissue repair as cosmetic and reconstructive surgery is a logical application, and theoretically the simplest application – for adipose-derived cell therapies since the isolated cells presumably do not need to display any transdifferentiation potential. Both ASCs and SVF cells have been approved and employed in clinical trials involving soft tissue defects. Breast reconstruction or augmentation trials have enrolled the greatest number of patients (143,146-148).

While clinicians have reported the transplant of SVF cells with autologous fat for cosmetic surgery (146,148), potential concerns remain for this application in postmastectomy breast cancer reconstruction (149). *In vitro* and *in vivo* data demonstrate that human ASCs secrete multiple cytokines that can increase the proliferation of active breast cancer cells (150).

Human adipose tissue grafting has been found to reduce cutaneous damage in rodents after burns or radiation exposure. Implantation of adipose tissue reduced fibrosis, improved collagen organization and increased the number of vessels, consistent with revascularization (151,152).

Adipose-derived cells and adipose tissue continue to be employed in preclinical models of soft tissue injury and are progressing into clinical trials. Cultured ASCs have been used to treat full-thickness skin wounds in diabetic rodents (153,154). The human ASC secretion of HGF, VEGF, and matrix metalloproteinases was correlated with the accelerated epithelialization and closure of the diabetic wounds (151,152,154).

Complementary studies using human ASCs demonstrate that similar mechanisms underlie their ability to promote repair in skeletal tissues (155-157). The use of SVF cells and ASCs for bone repair has been a target issue to many investigators. There are close developmental links between adipose tissue and bone, and it has been postulated that an inverse or reciprocal relationship exists between adipogenesis and osteogenesis at the cellular level (37,158,159). Their ability to undergo osteogenic differentiation without any stimulation when placed on an osteoconductive scaffold *in vivo* makes ASCs a promising candidate for skeletal tissue engineering (160). Furthermore, host dura mater (DM)-derived bone morphogenetic protein (BMP)-2 paracrine stimulation appears to play a key role in human adipose-derived stromal cells (hASC) mediated repair (161).

b. Ischemic Injuries

There has been increasing attention paid to the application of ASCs and SVF cells for the treatment of ischemic injuries, with particular interest in myocardial infarction (MI) (162,163). Improved function was attributed to the human ASC secretion of VEGF, FGF2 and SDF1α, and the subsequent recruitment of host-derived bone marrow progenitor

cells to the ischemic injury site (164). While a number of MI clinical trials are underway, it is too early for any major reports regarding patient outcomes. Further preclinical studies to document the paracrine and/or differentiation mechanism of ASC and SVF cell cardiac repair and their subsequent efficacy will likely accelerate the clinical translation process (165,166). The potential of adipose–derived cells to treat hind limb ischemia or stroke models has been investigated in several models as well (167,168).

c. **Immune Disorders**

In a manner similar to BMSCs, human ASC are known to display immunomodulatory and immuno-supresive function (50,106,169,170). The mechanism underlying ASC immunomodulatory function remains on the area of active investigation. Following disease initiation by immunization with collagen, intravenous administration of human ASCs reduced the levels of inflammatory cytokines and autoimmune Th1 cells (171). This was accompanied by an increased production of $CD4^+CD25^+FoxP3^+Tregs$ (171,172). In murine models of experimental colitis, intravenous administration of human ASCs reduced weight loss, inflammation and mortality. This was associated with reduced levels of inflammatory cytokines and increased level of IL-10. Furthermore, autoimmune Th1 cell proliferation decreased while the number of Tregs increased (173,174). These outcomes are consistent with multiple clinical trials that documented the beneficial effects of human ASCs in the treatment of Crohn's disease.

Multiple sclerosis is a progressive inflammatory disease affecting the myelinated cells of the central nervous system. Over time, this disease leads to degenerative changes and loss of cognitive, motor and sensory function; often, these changes occur in a waxing and waning manner. While the etiology of the disease remains a great question, there is compelling evidence supporting a role of an autoimmune component (143). *In vivo* studies have evaluated the immunomodulatory effects of ASCs in autoimmune and immunological disease. Chronic intravenous administration of human ASCs to a mouse model of systemic lupus erythematosus improved the animal's survival, decreased anti-DNA antibody level and increased the level of Tregs (175,176). In a murine model of GVHD, co-transplantation of ASCs with the hematopoietic stem cells significantly

reduced mortality, which is consistent with the immunosuppresive function of the ASCs *in vitro*. A single research group in China has reported anecdotal findings in GVHD patients treated with ASCs (133,177). Type 1 diabetes has attracted substantial attention as an autoimmune disease amenable to adipose-derived cell intervention. Following induction with a combination of activin, nicotinamide, and GLP-1, the differentiated ASCs expressed insulin and were capable of improving glucose sensitivity when transplanted into streptozotocin-induced diabetic mice (178). Similar *in vitro* and *in vivo* outcomes were obtained by an independent group using a $CD29^+CD44^+Sca1^+$ clonal population derived from murine epididymal ASCs (95,179).

d. **Gene Therapy**

Adipose-derived cells can be transduced with viral vectors and used effectively as gene delivery vehicles (180). Using an adeno-associated viral vector, investigators have transplanted ASCs transduced with α1-antitrypsin into the liver of mice (181). This approach documents the potential utility of ASCs to treat inborn metabolic errors involving the liver.

The application of ASCs and SVF cells is still in its infancy and the field has made progressive advances towards clinical applications (143).

Conclusions

ASCs are classified as adult multipotent stem cells and, as such, their multipotency is limited compared with ESCs and iPSCs. From a practical standpoint, however, numerous investigators have examined the practicalities of using ASCs for overcoming the limitations currently being faced in the various fields of regenerative medicine. ASCs have practical advantages in clinical medicine and their use has become more realistic because AT, the primary source of ASCs, is abundant and easy to obtain with less donor site morbidity. Only with reliable, standardized basic science research can real clinical progression be achieved. We look forward to seeing ASC *in vitro* research translated to beneficial clinical outcomes in the near future.

References:

1. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies. In Advances in Tissue Engineering: Stem Cells. New York: Mary Ann Liebert Inc, 2010, page 119-33.

2. Zuk PA, The Adipose-derived Stem Cell: Looking Back and Looking Ahead. Mol Biol Cell 2010; 21: 1783-7.

3. Bray GA, Medical Consequences of Obesity. J Clin Endocrinol Metab 2004; 89: 2583-9.

4. Katz AJ, Llull R, Hedrick MH, Futrell JW. Emerging Approaches to the Tissue Engineering of Fat. Clin Plast Surg 1999; 26: 587-603.

5. Gimble JM, Katz AJ, Bunnel BA. Adipose-Derived Stem Cells for Regenerative Medicine. Circ Res 2007; 100: 1249-60.

6. Liang L, Ma T, Chen W, Hu J, Bai X, Li J, et al. Therapeutic Potential and Related Signal Pathway of Adipose-Derived Stem Cell Transplantation for Rat Liver Injury. Hepatol Res 2009; 39: 822-32.

7. Kajiyama H, Hamazaki TS, Tokuhara M, Masui S, Okabayashi K, Ohnuma K, et al. Pdx1-transfected Adipose Tissue-derived Stem Cells Differentiate into Insulin-Producing Cells In Vivo and Reduce Hyperglycemia in Diabetic Mice. Int J Dev Biol 2010; 54: 699-705.

8. Sun N, Panetta NJ, Gupta DM, Wilson KD, Lee A, Jia F, et al. Feeder-free Derivation of Induced Pluripotent Stem Cells from Adult Human Adipose Stem Cells. Proc Natl Acad Sci USA 2009; 106: 15720-5.

9. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. Human Adipose Tissue is a Source of Multipotent Stem Cells. Mol Biol Cell 2002; 13: 4279-95.

10. Safford KM, Rice HE. Stem Cell Therapy for Neurologic Disorder: Therapeutic Potential of Adipose-Derived Stem Cells. Curr Drug Targets 2005; 6: 57-62.

11. Kilroy GE, Foster S, Wu X, Ruiz J, Sherwood S, Heifetz A, et al. Cytokine Profile of Human Adipose-Derived Stem Cells: Expression of Angiogenic, Hematopoietic, and Pro-Inflammatory Factors. J Cell Physiol. 2007; 212: 702-9.

12. Halvorsen YD, Bond A, Sen A, Franklin DM, Lea-Currie YR, Sujkowski D, et al. Thiazolidinediones and Glucocorticoids Synergistically Induce Differentiation of Human Adipose Tissue Stromal Cells: Biochemical, Cellular and Molecular Analysis. Metabolism 2001; 50: 407-13.

13. Sen A, Lea-Currie YR, Sujkowska D, Franklin DM, Wilkison WO, Halvorsen YD, et al. Adipogenic Potential of Human Adipose Derived Stromal Cells from Multiple Donors is Heterogeneous. J Cell Biochem 2001; 81: 312-9.

14. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies. Tissue Eng 2001; 7: 211-28.

15. Erickson GR, Gimble JM, Franklin DM, Rice HE, Awad H, Guilak F. Chondrogenic Potential of Adipose Tissue-Derived Stromal Cells In Vitro and In Vivo. Biochem Biophys Res Commun 2002; 290: 763-9.

16. Wickham MQ, Erickson GR, Gimble JW, Vail TP, Guilak F. Multipotent Stromal Cells Derived From the Infrapatellar Fat Pad of the Knee. Clin Orthop 2003; 412: 196-212.

17. Corre J, Barreau C, Cousin B, Chavoin JP, Caton D, Fournial G, Penicaud L, et al. Human Subcutaneous Adipose Cells Support Complete Differentiation but not Self-Renewal of Hematopoeitic Progenitors. J Cell Physiol 2006; 208: 282-8.

18. Seo MJ, Suh SY, Bae YC, Jung JS. Differentiation of Human Adipose Stromal Cells into Hepatic Lineage In Vitro and In Vivo. Biochem Biophys Res Commun 2005; 328: 258-64.

19. Talens-Visconti R, Bonora A, Jover R, Mirabet V, Carbonell F, Castell JV, et al. Human Mesenchymal Stem Cells from Adipose Tissue: Differentiation into Hepatic Lineage. Toxicol In Vitro 2007; 21: 324-9.

20. Talens-Visconti R, Bonora A, Jover R, Mirabet V, Carbonell F, Castell JV, et al. Hepatogenic Differentiation of Human Mesenchymal Stem Cells from Adipose Tissue in Comparison with Bone Marrow Mesenchymal Stem Cells. World J Gastroenterol 2006; 12: 5834-45.

21. Safford KM, Hicok KC, Safford SD, Halvorsen YD, Wilkison WO, Gimble JM, et al. Neurogenic Differentiation of Murine and Human Adipose-Derived Stromal Cells. Biochem Biophys Res Commun 2002; 294: 371-9.

22. Safford KM, Safford SD, Gimble JM, Shetty AK, Rice HE. Characterization of Neuronal/Glial Differentiation of Murine Adipose-Derived Adult Stromal Cells. Exp Neurol 2004; 187: 319-28.

23. Kang SK, Putnam LA, Ylostalo J, Popescu IR, Dufour J, Belousov A, Bunnel BA. Neurogenesis of Rhesus Adipose Stromal Cells. J Cell Sci 2004; 117: 4289-99.

24. Krampera M, Marconi S, Pasini A, Galie M, Rigotti G, Mosna F, et al. Induction of Neural-Like Differentiation in Human Mesenchymal Stem Cells Derived from Bone Marrow, Fat, Spleen and Thymus. Bone 2007; 40: 382-90.

25. Halvorsen YC, Wilkison WO, Gimble JM. Adipose-Derived Stromal Cells-Their Utility and Potential in Bone Formation. Int J Obes Relat Metab Disord 2000; 24(suppl 4): S41-4.

26. Halvorsen YD, Franklin D, Bond AL, Hitt DC, Auchter C, Boskey AL, et al. Extracellular Matrix Mineralization and Osteoblast Gene Expression by Human Adipose Tissue-Derived Stromal Cells. Tissue Eng 2001; 7: 729-41.

27. Huang JI, Beanes SE, Zhu M, Lorenz HP, Hedrick MH, Benhaim P. Rat Extramedullary Adipose Tissue as a Source of Osteochondrogenic Progenitor Cells. Plast Reconstr Surg 2002; 109: 1033-41.

28. Timper K, Seboek D, Eberhardt M, Linscheid P, Christ-Crain M, Keller U, et al. Human Adipose Tissue-Derived Mesenchymal Stem Cells Differentiate into Insulin, Somatostatin, and Glucagon Expressing Cells. Biochem Biophys Res Commun 2006; 341: 1135-40.

29. Lee JH, Kemp DM. Human Adipose-Derived Stem Cells Display Myogenic Potential and Perturbed Function in Hypoxic Conditions. Biochem Biophys Res Commun 2006; 341: 882-8.

30. Mizuno H, Zuk PA, Zhu M, Lorenz HP, Benhaim P, Hedrick MH. Myogenic Differentiation by Human Processed Lipoaspirate Cells. Plast Reconstr Surg 2002; 109: 199-209.

31. Kershaw EE, Flier JS. Adipose Tissue as an Endocrine Organ. J Clin Endocrinol Metab 2004; 89: 2548-56.

32. Spiegelman BM, Flier JS. Adipogenesis and Obesity: Rounding Out the Big Picture. Cell 1996; 87: 377-89.

33. Trayhurn P. Adipocyte Biology. Obes Rev 2007; 8 (Suppl 1): 41-4.

34. Shen JF, Sugawara A, Yamashita J, Ogura H, Sato S. Dedifferentiated Fat Cells: An Alternative Source of Adult Multipotent Cells from the Adipose Tissues. Int J Oral Sci 2011; 3: 117-24.

35. Himms-Hagen J. Brown Adipose Tissue Thermogenesis: Inter-disciplinary Studies. Faseb J 1990; 4: 2890-8.

36. Ailhaud G, Grimaldi P, Negrel R. Cellular and Molecular Aspects of Adipose Tissue Development. Annu Rev Nutr 1992; 12: 207-33.

37. Gimble JM, Robinson CE, Wu X, Kelly KA. The Function of Adipocytes in the Bone Marrow Stroma: an Update. Bone 1996; 19: 421-8.

38. Casteilla L, Dani C. Adipose Tissue-Derived Cells: from Physiology to Regenerative Medicine. Diabetes Metab 2006; 32: 393-401.

39. Bjorntorp P, Gustafson A, Persson B. Adipose Tissue Fat Cell Size and Number in Relation to Metabolism in Endogenous Hypertriglyceridemia. Acta Med Scand 1971; 190: 363-7.

40. Hirsch J, Batchelor B. Adipose Tissue Cellularity in Human Obesity. Clin Endocrinol Metab 1976; 5: 299-311.

41. van Harmelen V, Skurk T, Rohrig K, Lee YM, Halbleib M, Aprath-Husmann I, *et al.* Effect of BMI and Age on Adipose Tissue Cellularity and Differentiation Capacity in Women. Int J Obes Relat Metab Disord 2003; 27: 889-95.

42. Arner E, Westermark PO, Spalding KL, Britton P, Ryden M, Frisen J, *et al.* Adipocyte Turnover: Relevance to Human Adipose Tissue Morphology. Diabetes 2010; 59: 105-9.

43. Jo J, Gavrilova O, Pack S, Jou W, Mullen S, Sumner AE, *et al.* Hypertrophy and/or Hyperplasia: Dynamics of Adipose Tissue Growth. PLos Comput Biol 2009; 5: e1000324.

44. Butterwith SC. Regulators of Adipocyte Precursor Cells. Poult Sci 1997; 76: 118-23.

45. Hausman DB, DiGirolamo M, Bartness TJ, Hausman GJ, Martin RJ. The Biology of White Adipocyte Proliferation. Obes Rev 2001; 2: 239-54.

46. Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, *et al.* Dynamics of Fat Cell Turnover in Humans. Nature 2008; 453: 783-7.

47. Planat-Benard V, Silvestre JS, Cousin B, Andre M, Nibbelink M, Tamarat R, *et al.* Plasticity of Human Adipose Lineage Cells Toward Endothelial Cells: Physiological and Therapeutic Perspectives. Circulation 2004; 109: 656-63.

48. Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE, *et al.* Secretion of Angiogenic and Antiapoptotic Factors by Human Adipose Stromal Cells. Circulation 2004; 109: 1292-8.

49. Miranville A, Heeschen C, Sengenes C, Curat CA, Busse R, Bouloumie A. Improvement of Postnatal Neovascularization by Human Adipose Tissue-Derived Stem Cells. Circulation 2004; 110: 349-55.

50. Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, *et al.* Immunomodulatory Effect of Human Adipose Tissue-Derived Adult Stem Cells: Comparison with Bone Marrow Mesenchymal Stem Cells. Br J Haematol 2005; 129: 118-29.

51. Yanez R, Lamana ML, Garcia-castro J, Colmenero I, Ramirez M, Bueren JA. Adipose Tissue-Derived Mesenchymal Stem Cells Have *In Vivo* Immunosuppresive Properties Applicable for the Control of the Graft-Versus-Host Disease. Stem Cells 2006; 24: 2582-91.

52. Yoshimura K, Suga H, Eto H. Adipose-Derived Stem/Progenitor Cells: Roles in Adipose Tissue Remodeling and Potential Use for Soft Tissue Augmentation. Regen Med 2009; 4: 265-73.

53. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is Associated with Macrophage Accumulation in Adipose Tissue. J Clin Invest 2003; 112: 1796-808.

54. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, *et al.* Chronic Inflammation in Fat Plays a Crucial Role in the Development of Obesity-Related Insulin Resistance. J Clin Invest 2003; 112: 1821-30.

55. Schipper BM, Marra KG, Zhang W, Donnenberg AD, Rubin JP. Regional Anatomic and Age Effects on Cell Function of Human Adipose-Derived Stem Cells. Ann Plast Surg 2008; 60: 538-44.

56. Prunet-Marcassus B, Cousin B, Caton D, André M, Pénicaud L, Casteilla L. From Heterogeneity to Plasticity in Adipose Tissue: Site Specific Differences. Exp Cell Res 2006; 312: 727-36.

57. Helder MN, Knippenberg M, Klein-Nulend J, Wuisman PI. Stem Cells from Adipose Tissue Allow Challenging New Concepts for Regenerative Medicine. Tissue Eng 2007; 13: 1799-808.

58. Schaffler A, Buchler C. Concise Review: Adipose Tissue-Derived Stromal Cells-Basic and Clinical Implications for Novel Cell-Based Therapies. Stem Cells 2007; 25: 818-27.

59. Housman TS, Lawrence N, Mellen BG, George MN, Fillippo JS, Cerveny KA, *et al.* The Safety of Liposuction: Results of a National Survey. Dermatol Surg 2002; 28: 971-8.

60. Strem BM, Hicok KC, Zhu M, Wulur I, Alfonso Z, Schreiber RE, *et al.* Multipotential Differentiation of Adipose Tissue-Derived Stem Cells. Keio J Med 2005; 54: 132-41.

61. Gimble JM, Bunnell BA, Chiu ES, Guilak F. Concise Review: Adipose-Derived Stromal Vascular Fraction Cells and Stem Cells : Let's Not Get Lost in Translation. Stem Cells 2011; 29: 749-54.

62. Boquest AC, Shahdadfar A, Frønsdal K, Sigurjonsson O, Tunheim SH, Collas P, *et al.* Isolation and Transcription Profiling of Purified Uncultured Human Stromal Stem Cells: Alteration of Gene Expression After In Vivo Cell Culture. Mol Biol Cell 2005; 16: 1131-41.

63. Mitchell JB, McIntosh K, Zvonic S, Garrett S, Floyd ZE, Kloster A, *et al.* Immunophenotype of Human Adipose-Derived Cells : Temporal Changes in Stromal-Associated and Stem Cell-Associated Markers. Stem Cells 2006; 24: 376-85.

64. Tholpady SS, Llull R, Ogle RC, Rubin JP, Futrell JW, Katz AJ. Adipose Tissue: Stem Cells and Beyond. Clin Plast Surg 2006; 33: 55-62.

65. Yoshimura K, Shigeura T, Matsumoto D, Sato T, Takaki Y, Aiba-Kojima E, *et al.* Characterization of Freshly Isolated and Cultured Cells Derived from the Fatty and Fluid Portions of Liposuction Aspirates. J Cell Physiol 2006; 208: 64-76.

66. Suga H, Matsumoto D, Inoue K, Shigeura T, Eto H, Aoi N, *et al.* Numerical Measurement of Viable and Nonviable Adipocytes and Other Cellular Components in Aspirated Fat Tissue. Plast Reconstr Surg 2008; 122: 103-14.

67. Boquest AC, Shahdadfar A, Brinchmann JE, Collas P. Isolation of Stromal Stem Cells from Human Adipose Tissue. Methods Mol Biol 2006; 325: 35-46.

68. Katz AJ, Tholpady A, Tholpady SS, Shang H, Ogle RC. Cell Surface and Transcriptional Characterization of Human Adipose-Derived Adherent Stromal (hADAS) Cells. Stem Cells 2005; 23: 412-23.

69. Mizuno H, Tobita M, Uysal AC. Concise Review: Adipose-Derived Stem Cells as a Novel Tool for Future Regenerative Medicine. Stem Cells 2012; 30: 804-10.

70. De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, Zhu M, *et al.* Comparison of Multilineage Cells From Human Adipose Tissue and Bone Marrow. Cells Tissues Organs 2003; 174: 101-9.

71. Izadpanah R, Trygg C, Patel B, Kriedt C, Dufour J, Gimble JM, *et al.* Biologicic Properties of Mesenchymal Stem Cells Derived from Bone Marrow and Adipose Tissue. J Cell Biochem 2006; 99: 1285-97.

72. Hebert TL, Wu X, Yu G, Goh BC, Halvorsen YD, Wang Z, *et al.* Culture Effects of Epidermal Growth Factor (EGF) and Basic Fibroblast Growth Factor (BFGF) on Cryopreserved Human Adipose-Derived Stromal/Stem Cell Proliferation and Adipogenesis. J Tissue Eng Regen Med 2009; 3: 553-61.

73. Kras KM, Hausman DB, Martin RJ. Tumor Necrosis Factor-Alpha Stimulates Cell Proliferation in Adipose Tissue-Derived Stromal-Vascular Cell Culture: Promotion of Adipose Tissue Expansion by Paracrine Growth Factors. Obes Res 2000; 8: 186-93.

74. Zaragosi LE, Ailhaud G, Dani C. Autocrine Fibroblast Growth Factor 2 Signalling is Critical for Self-Renewal of Human Multipotent Adipose-Derived Stem Cells. Stem Cells 2006; 24: 2412-9.

75. Kang YJ, Jeon ES, Song HY, Woo JS, Jung JS, Kim YK, et al. Role of c-jun N-terminal kinase in the pdgf-induced proliferation and migration of human adipose tissue-derived mesenchymal stem cells. J Cell Biochem 2005; 95: 1135-45.

76. Song HY, Jeon ES, Jung JS, Kim JH. Oncostation M Induces Proliferation of Human Adipose Tissue-Derived Mesenchymal Stem Cells. Int J Biochem Cell Biol 2005; 37: 2357-65.

77. Kakudo N, Minakata T, Mitsui T, Kushida S, Notodihardjo FZ, Kusumoto K. Proliferation-Promoting Effect of Platelet-Rich Plasma on Human Adipose-Derived Stem Cells and Human Dermal Fibroblast. Plast Reconstr Surg 2008; 122: 1352-60.

78. Blande IS, Bassaneze V, Lavini-Ramos C, Fae KC, Kalil J, Miyakawa AA, et al. Adipose Tissue Mesenchymal Stem Cell Expansion in Animal Serum-Free Medium Supplemented with Autologous Human Platelet Lysate. Transfusion 2009; 49: 2680-5.

79. Freyberg S, Song YH, Muehlberg F, Alt E. Thrombin Peptide (tp508) Promotes Adipose Tissue-Derived Stem Cell Proliferation via pi3 Kinase/Akt Pathway. J Vasc Res 2009; 46: 98-102.

80. Brayfield CA, Marra KG, Rubin JP. Adipose Tissue Regeneration. Curr Stem Cell Res Ther 2010; 5: 116-21.

81. Cherubino M, Marra KG. Adipose-Derived Stem Cells for Soft Tissue Reconstruction. Regen Med 2009; 4: 109-17.

82. Rubin JP, Marra KG. Soft Tissue Reconstruction. Methods Mol Biol 2011; 702: 395-400.

83. Dragoo JL, Samimi B, Zhu M, Hame SL, Thomas BJ, Lieberman JR, et al. Tissue-Engineering Cartilage and Bone Using Stem Cells From Human Infrapatellar Fat Pads. J Bone Joint Surg Br 2003; 85: 740-7.

84. Estes BT, Diekman BO, Gimble JM, Guilak F. Isolation of Adipose-Derived Stem Cells and Their Induction to a Chondrogenic Phenotype. Nat Protoc 2010; 5: 1294-1311.

85. Estes BT, Guilak F. Three-Dimensional Culture Systems to Induce Chondrogenesis of Adipose-Derived Stem Cells. Methods Mol Biol 2011; 702: 201-17.

86. Lee WC, Sepulveda JL, Rubin JP, Marra KG. Cardiomyogenic Differentiation Potential of Human Adipose Precursor Cells. Int J Cardiol 2009; 133: 399-401.

87. Planat-Bénard V, Menard C, André M, Puceat M, Perez A, Garcia-Verdugo JM, et al. Spontaneous Cardiomyocyte Differentiation from Adipose Tissue Stroma Cells. Circ Res 2004; 94: 223-9.

88. Cherubino M, Rubin JP, Miljkovic N, Kelmendi-Doko A, Marra KG. Adipose-Derived Stem Cells for Wound Healing Applications. Ann Plast Surg 2011; 66: 210-5.

89. Uysa AC, Mizuno H. Tendon Regeneration and Repair with Adipose Derived Stem Cells. Curr Stem Cell Res Ther 2010; 5: 161-7.

90. Tobita M, Mizuno H. Periodontal Disease and Periodontal Tissue Regeneration. Curr Stem Cell Res Ther 2010; 5: 168-74.

91. Mesimäki K, Lindroos B, Törnwall J, Mauno J, Lindqvist C, Kontio R, et al. Novel Maxillary Reconstruction with Ectopic Bone Formation by GMP Adipose Stem Cells. Int J Oral Maxillofac Surg 2009; 38: 201-9.

92. Lendeckel S, Jödicke A, Christophis P, Heidinger K, Wolff J, Fraser JK, et al. Autologous Stem Cells (Adipose) and Fibrin Glue Used to Treat Widespread Traumatic Calvarial Defects : Case Report. J Craniomaxillofac Surg 2004; 32: 370-3.

93. Aurich H, Sgodda M, Kaltwasser P, Vetter M, Weise A, Liehr T, et al. Hepatocyte Differentiation of Mesenchymal Stem Cells from Human Adipose Tissue In Vitro Promotes Hepatic Integration In Vivo. Gut 2009; 58: 570-81.

94. Banas A, Teratani T, Yamamoto Y, Tokuhara M, Takeshita F, Osaki M, et al. Rapid Hepatic Fate Specification of Adipose-Derived Stem Cells and Their Therapeutic Potential for Liver Failure. J Gastroenterol Hepatol 2009; 24: 70-7.

95. Chandra V, G S, Phadnis S, Nair PD, Bhonde RR. Generation of Pancreatic Hormone-Expressing Islet-Like Cells Aggregates from Murine Adipose Tissue-Derived Stem Cells. Stem Cells 2009; 27: 1941-53.

96. Locke M, Feisst V, Dunbar PR. Concise Review: Human Adipose-Derived Stem Cells : Separating Promise from Clinical Need. Stem Cells 2011; 29: 404-11.

97. Kilroy GE, Foster SJ, Wu X, Ruiz J, Sherwood S, Heifetz A, et al. Cytokine Profile of Human Adipose-Derived Stem Cells : Expression of Angiogenic, Hematopoietic, and Pro-Inflammatory Factors. J Cell Physiol 2007; 212: 702-9.

98. Kim WS, Park BS, Sung JH. Protective Role of Adipose-Derived Stem Cells and Their Soluble Factors in Photoaging. Arch Dermatol Res 2009; 301: 329-36.

99. Salgado AJ, Reis RL, Sousa NJ, Gimble JM. Adipose Tissue Derived Stem Cells Secretome : Soluble Factors and Their Roles in Regenerative Medicine. Curr Stem Cell Res 2010; 5: 103-10.

100. Young C, Jarrell BE, Hoying JB, Williams SK. A Porcine Model for Adipose Tissue-Derived Endothelial Cell Transplantation. Cell Transplant 1992; 1: 293-8.

101. Williams SK, Wang TF, Castrillo R, Jarrell BE. Liposuction-Derived Human Fat Used for Vascular Graft Sodding Contains Endothelial Cells and Not Mesothelial Cells as the Major Cell Type. J Vasc Surg 1994; 19: 916-23.

102. Stashower M, Smith K, Williams J, Skelton H. Stromal Progenitor Cells Present Within Liposuction and Reduction Abdominoplasty Fat for Autologous Transfer to Aged Skin. Dermatol Surg 1999; 25: 945-9.

103. Gronthos S, Franklin DM, Leddy HA, Robey PD, Storms RW, Gimble JM. Surface Protein Characterization of Human Adipose Tissue-Derived Stromal Cells. J Cell Physiol 2001; 189: 54-63.

104. Aust L, Devlin B, Foster SJ, Halvorsen YD, Hicok K, du Laney T, et al. Yield of Human Adipose-Derived Adult Stem Cells from Liposuction Aspirates. Cytotherapy 2004; 6: 7-14.

105. Case J, Horvath TL, Howell JC, Yoder MC, March KL, Srour EF. Clonal Multilineage Differentiation of Murine Common Pluripotent Stem Cells Isolated from Skeletal Muscle and Adipose Stromal Cells. Ann N Y Acad Sci 2005; 1044: 183-200.

106. McIntosh K, Zvonic S, Garrett S, Mitchell JB, Floyd ZE, Hammill L, et al. The Immunogenicity of Human Adipose-Derived Cells: Temporal Changes In Vitro. Stem Cells 2006; 24: 1245-53.

107. Nakagami H, Maeda K, Morishita R, Iguchi S, Nishikawa T, Takami Y, et al. Novel Autologous Cell Therapy in Ischemic Limb Disease Through Growth Factor Secretion by Cultured Adipose Tissue-Derived Stromal Cells. Arterioscler Thromb Vasc Biol 2005; 25: 2542-7.

108. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage Potential of Adult Human Mesenchymal Stem Cells. Science 1999; 284: 143-7.

109. Young HE, Steele TA, Bray RA, Detmer K, Blake LW, Lucas PW, et al. Human Pluripotent and Progenitor Cells Display Cell Surface Cluster Differentiation Markers CD10, CD13, CD56 and MHC Class I. Proc Soc Exp Biol Med 1999; 221: 63-71.

110. Kratchmarova I, Kalume DE, Blagoev B, Scherer PE, Podtelejnikov AV, Molina H, et al. A Proteomic Approach for Identification of Secreted Proteins During the Differentiation of 3t3-11 Preadipocytes to Adipocytes. Mol Cell Proteomics 2002; 1: 213-22.

111. Delany J, Floyd ZE, Zvonic S, Smith A, Gravois A, Reiners E, *et al.* Proteomic Analysis of Primary Cultures of Human Adipose Derived Stem Cells: Modulation by Adipogenesis. Mol Cell Proteomics 2005; 4: 731-40.

112. Celis JE, Moreira JM, Cabezon T, Gromov P, Friis E, Rank F, *et al.* Identification od Extracellular and Intracellular Signaling Components of the Mammary Adipose Tissue and Its Interstisial Fluid in High Risk Breast Cancer Patients : Toward Dissecting the Molecular Circuitry of Epithelial-Adipocyte Stromal Cell Interactions. Mol Cell Proteomics 2005; 4: 492-522.

113. Welsh GI, Griffiths MR, Webster KJ, Page MJ, Tavare JM. Proteome Analysis of Adipogenesis. Proteomics 2004; 4: 1042-51.

114. Chen X, Cushman SW, Pannell LK, Hess S. Quantitative Proteomic Analysis of the Secretory Proteins from Rat Adipose cells using a 2D Liquid Chromatography-MS/MS Approach. J Proteome Res 2005; 4: 570-7.

115. Zvonic S, Lefevre M, Kilroy G, Floyd ZE, Delany JP, Kheterpal I, *et al.* Secretome of Primary Cultures of Human Adipose-Derived Stem Cells: Modulation of Serpins by Adipogenesis. Mol Cell Proteomics 2007; 6: 18-28.

116. Hausman GJ, Poulos SP, Richardson RL, Barb CR, Andacht T, Kirk HC, *et al.* Secreted Proteins and Genes in Fetal and Neonatal Pig Adipose Tissue and Stromal-Vascular Cells. J Anim Sci 2006; 84: 1666-81.

117. Wang D, Park JS, Chu JS, Krakowski A, Luo K, Chen DJ, *et al.* Proteomic Profiling of Bone Marrow Mesenchymal Stem Cells Upon Transforming Growth Factor Beta 1 Stimulation. J Biol Chem 2004; 279: 43725-34.

118. Sun HJ BY, Choi YR, Shim JH, Han SH, Lee YW. A Proteomic Analysis During Serial Subculture and Osteogenic Differentiation of Human Mesenchymal Stem Cell. J Orthop Res 2006; 24: 2059-71.

119. Zimmerlin L, Donnenberg VS, Pfeifer ME, Meyer EM, Péault B, Rubin JP, *et al.* Stromal Vascular Progenitors in Adult Human Adipose Tissue. Cytometry A 2010; 77: 22-30.

120. Musina RA, Bekchanova ES, Sukhikh GT. Comparison of Mesenchymal Stem Cells Obtained from Different Human Tissues. Bull Exp Biol Med 2005; 139: 504-9.

121. Bailey AM, Kapur S, Katz AJ. Characterization of Adipose-Derived Stem Cells : An Update. Curr Stem Cell Res Ther 2010; 5: 95-102.

122. Basciano L, Nemos C, Foliguet B, de Isla N, de Carvalho M, Tran N, *et al.* Long Term Culture of Mesenchymal Stem Cells in Hypoxia Promotes a Genetic Program Maintaining Their Undifferentiated and Multipotent Status. BMC Cell Biol 2011; 12: 12.

123. Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, *et al.* Human Bone Marrow Derived Mesenchymal Stem Cells Do Not Undergo Transformation After Long-Term In *Vitro* Culture and Do Not Exhibit Telomere Maintenance Mechanisms. Cancer Res 2007; 67: 9142-9.

124. Deans RJ, Moseley AB. Mesenchymal Stem Cells : Biology and Potential Clinical Uses. Exp Hematol 2000; 28: 875-84.

125. Folgiero V, Migliano E, Tedesco M, Iacovelli S, Bon G, Torre ML, *et al.* Purification and Characterization of Adipose-Derived Stem Cells from Patients with Lipoaspirate Transplant. Cell Transplant 2010; 19: 1225-35.

126. Freitas CS, Dalmau SR. Multiple Sources of Non-Embryonic Multipotent Stem Cells : Processed Lipoaspirates and Dermis As Promising Alternatives to Bone Marrow-Derived Cell Therapies. Cell Tissue Res 2006; 325: 403-11.

127. Jones EA, English A, Kinsey SE, Straszynski L, Emery P, Ponchel F, *et al.* Optimization of a Flow Cytometry-Based Protocol for Detection and Phenotypic Characterization of Multipotent Mesenchymal Stromal Cells from Human Bone Marrow. Cytometry B Clin Cytom 2006; 70: 391-9.

128. Meyerrose TE, De Ugarte DA, Hofling AA, Herrbrich PE, Cordonnier TD, Shultz LD, *et al. In Vivo* Distribution of Human Adipose-Derived Mesenchymal Stem Cells in Novel Xenotransplantation Models. Stem Cells 2007; 25: 220-7.

129. Alipour R, Sadeghi F, Hashemi-Beni B, Zarkesh-Esfahani SH, Heydari F, Mousavi SB, *et al.* Phenotypic Characterization and Comparison of Adult Dental Stem Cells with Adipose Derived Stem Cells. Int J Prev Med 2010; 1: 164-71.

130. Delorme B, Ringe J, Gallay N, Le Vern Y, Kerboeuf D, Jorgensen C, *et al.* Specific Plasma Membrane Protein Phenotype of Culture-Amplified and Native Human Bone Marrow Mesenchymal Stem Cells. Blood 2008; 111: 2631-5.

131. Role of CD9 in Proliferation and Proangiogenic Action of Human Adipose-Derived Mesenchymal Stem Cells. Pflugers Arch 2007; 455: 283-96.

132. Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, *et al.* Comparative Characteristics of Mesenchymal Stem Cells From Human Bone Marrow, Adipose Tissue, and Umbilical Cord Blood. Exp Hematol 2005; 33: 1402-16.

133. Fang B, Song Y, Liao L, Zhang Y, Zhao RC. Favorable Response to Human Adipose Tissue-Derived Mesenchymal Stem Cells in Steroid-Refractory Acute Graft-Versus-Host Disease. Transplant Proc 2007; 39: 3358-62.

134. Gimble JM, Bunnell BA, Guilak F. Human Adipose-Derived Cells: an Update on the Transition to Clinical Translation. Regen Med 2012; 7: 225-35.

135. Hicok KC, Hedrick MH. Automated Isolation and processing of Adipose-Derived Stem and Regenerative Cells. Methods Mol Biol 2011; 702: 87-105.

136. NIH. Registry and Results Database of Federally and Privately Supported Clinical Trials Conducted in the USA and Around the World (2011). http://clinicaltrials.gov

137. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, *et al.* Minimal Criteria for Defining Multipotent Mesenchymal Stromal Cells. The International Society for Cellular Therapy Position Statement. Cytotherapy 2006; 8: 315-7.

138. Smas CM, Sul HS. Pref-1, a Protein Containing EGF-like Repeats, Inhibits Adipocyte Differentiation. Cell 1993; 73: 725-34.

139. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, *et al.* A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human Organs. Cell Stem Cells 2008; 3: 301-13.

140. Traktuev DO, Merfeld-Clauss S, Li J, Kolonin M, Arap W, Pasqualini R, *et al.* A Population of Multipotent CD34-Positive Adipose Stromal Cells Share pericyte and Mesenchymal Surface Markers, Reside in a Periendothelial Location, and Stabilize Endothelial Network. Circ Res 2008; 102: 77-85.

141. Amos PJ, Shang H, Bailey AM, Taylor A, Katz AJ, Peirce SM. IFATS Collection: The Role of Human Adipose-Derived Stromal Cells in Inflammatory Microvascular Remodeling and Evidence of Perivascular Phenotype. Stem Cells 2008; 26: 2682-90.

142. Zannettino AC, Paton S, Arthur A, Khor F, Itescu S, Gimble JM, *et al.* Multipotential Human Adipose-Derived Stromal Stem Cells Exhibit a Perivascular Phenotype In *Vitro* and In *Vivo*. J Cell Physiol 2008; 214: 413-21.

143. Gimble JM, Guilak F, Bunnell BA. Clinical and Preclinical Translation of Cell-based Therapies Using Adipose Tissue-Derived Cells. Stem Cell Res Ther 2010; 1: 19.

144. Baer PC. Adipose-Derived Stem Cells and Their Potential to Differentiate into the Epithelial Lineage. Stem Cells Dev 2011; 20: 1805-16.

145. Fraser JK, M Zhu, I Wulur, Z Alfonso. Adipose-Derived Stem Cells. Methods Mol Biol 2008; 449: 59-67.

146. Matsumoto D, Sato K, Gonda K, Takaki Y, Shigeura T, Sato T, et al. Cell-Assisted Lipotransfer (CAL): Supportive Use of Human Adipose-Derived Cells for Soft Tissue Augmentation with Lipoinjection. Tissue Eng 2006; 12: 3375-82.

147. Yoshimura K, Sato K, Aoi N, Kurita M, Inoue K, Suga H, et al. Cell-Assisted Lipotransfer for Cosmetic Breast Augmentation: Supportive Use of Adipose-Derived Stem/Stromal Cells. Aesthetic Plast Surg 2008; 32: 48-55; discussion 56-57.

148. Yoshimura K, Asano Y, Aoi N, Kurita M, Oshima Y, Sato K, et al. Progenitor-Enriched Adipose Tissue Transplantation as Rescue for Breast Implant Complications. Breast J 2010; 16: 169-75.

149. Pearl RA, Leedham SJ, Pacifico MD. The Safety of Autologous Fat Transfer in Breast Cancer: Lessons from Stem Cell Biology. J Plast Reconstr Aesthet Surg. 2012; 65: 283-8.

150. Zimmerlin L, Donnenberg AD, Rubin JP, Basse P, Landreneau RJ, Donnenberg VS. Regenerative Therapy and Cancer: In Vitro and In Vivo Studies of the Interaction Between Adipose-Derived Stem Cells and Breast Cancer Cells from Clinical Isolates. Tissue Eng Part A 2011; 17: 93-106.

151. Sultan SM, Barr JS, Butala P, Davidson EH, Weinstein AL, Knobel D, et al. Fat Grafting Accelerates Revascularization and Decreases Fibrosis Following Thermal Injury. J Plast Reconstr Aesthet Surg 2011; 65: 219-27.

152. Sultan SM, Stern CS, Allen RJ Jr, Thanik VD, Chang CC, Nguyen PD, et al. Human Fat Grafting Alleviates Radiation Skin Damage in a Murine Model. Plast Reconstr Surg 2011; 128: 363-72.

153. Nie C, Yang D, Xu J, Si Z, Jin X, Zhang J. Locally Administered Adipose-Derived Stem Cells Accelerate Wound Healing Through Differentiation and Vasculogenesis. Cell Transplant 2011; 20: 205-16.

154. Amos PJ, Kapur SK, Stapor PC, Shang H, Bekiranov S, Khurgel M, et al Human Adipose-Derived Stromal Cells Accelerate Diabetic Wound Healing: Impact on Cell Formulation and Delivery. Tissue Eng Part A 2010; 16: 1595-606.

155. Lee K, Kim H, Kim JM, Kim JR, Kim KJ, Kim YJ, et al. Systemic Transplantation of Human Adipose-Derived Stem Cells Stimulates Bone Repair by Promoting Osteoblast and Osteoclast Function. J Cell Mol Med 2011; 15: 2082-94.

156. Levi B, James AW, Nelson ER, Peng M, Wan DC, Commons GW, et al. Acute Skeletal Injury is Necessary for Human Adipose-Derived Stromal Cell-Mediated Calvarial Regeneration. Plast Reconstr Surg 2011; 127: 1118-29.

157. Levi B, James AW, Nelson ER, Vistnes D, Wu B, Lee M, et al. Human Adipose-Derived Stromal Cells Heal Critical Size Mouse Calvarial Defects. PLos One 2010; 5: E11177.

158. Gimble JM. The Function of Adipocytes in the Bone Marrow Stroma. New Biol 1990; 2: 304-12.

159. Gimble JM, Zvonic S, Floyd ZE, Kassem M, Nuttal ME. Playing with Bone and Fat. J Biol Chem 2006; 98: 251-66.

160. Levi B, Longaker MT. Concise Review: Adipose-Derived Stromal Cells for Skeletal Regenerative Medicine. Stem Cells 2011; 29: 576-82.

161. Levi B, Nelson ER, Li S, James AW, Hyun JS, Montoro DT, et al. Dura Matter Stimulates Human Adipose-Derived Stromal Cells to Undergone Bone Formation in Mouse Calvarian Defects. Stem Cells 2011; 29: 1241-55.

162. Bai X, Alt E. Myocardial Regeneration Potential of Adipose Tissue-Derived Stem Cells. Biochem Biophys Res Commun 2010; 401: 321-6.

163. Mazo M, Gavira JJ, Pelacho B, Prosper F. Adipose-Derived Stem Cells for Myocardial Infarction. J Cardiovasc Transl Res 2011; 4: 145-53.

164. Ii M, Horii M, Yokoyama A, Shoji T, Mifune Y, Kawamoto A, et al. Synergistic Effect of Adipose-Derived Stem Cell Therapy and Bone Marrow Progenitor Recruitment in Ischemic Heart. Lab Invest 2010; 91: 539-52.

165. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue. Stem Cells 2006; 24: 1294-301.

166. Sensebe L, Bourin P, Tarte K. Good Manufacturing Practices Production of Mesenchymal Stem/Stromal Cells. Hum Gene Ther 2011; 22: 19-26.

167. Dromard C, Bourin P, Andre M, De Barros S, Casteilla L, Planat-Benard V. Human Adipose Derived Stroma/Stem Cells Grow in Serum-Free Medium as Floating Spheres. Exp Cell Res 2011; 317": 770-80.

168. Rajala K, Lindroos B, Hussein SM, Lappalainen RS, Pekkanen-Mattila M, Inzunza J, et al. A Defined and Xeno-Free Culture Method Enabling the Establishment of Clinical-Grade Human Embryonic, Induced Pluripotent and Adipose Stem Cells. PLoS One 2010; 5: E10246

169. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal Stem Cells Supress Lymphocyte Proliferation In Vitro and Prolong Skin Graft Survival In Vivo. Exp Hematol 2002; 30: 42-8.

170. Ivanova-Todorova E, Bochev I, Mourdjeva M, Dimitrov R, Bukarev D, Kyurkchiev S, et al. Adipose Tissue-Derived Mesenchymal Stem Cells Are More Potent Suppressors of Dendritic Cells Differentiation Compared with Bone Marrow-Derived Mesenchymal Stem Cells. Immunol Lett 2009; 126: 37-42.

171. González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. Treatment of Experimental Arthritis by Inducing Immune Tolerance with Human Adipose-Derived Mesenchymal Stem Cells. Arthritis Rheum 2009; 60: 1006-19.

172. Gonzalez-Rey E, Gonzalez MA, Varela N, O'Valle F, Hernandez-Cortes P, Rico L, et al. Human Adipose-Derived Mesenchymal Stem Cells Reduce Inflammatory and T-Cell Responses and Induce Regulatory T-Cells In Vitro in Rheumatoid Arthritis. Ann Rheum Dis 2010; 69: 241-8.

173. González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. Adipose-Derived Mesenchymal Stem Cells Alleviate Experimental Colitis by Inhibiting Inflammatory and Autoimmune Response. Gastroenterology 2009; 136: 978-89.

174. Gonzalez-Rey E, Anderson P, González MA, Rico L, Büscher D, Delgado M. Human Adult Stem Cells Derived from Adipose Tissue Protect Against Experimental Colitis and Sepsis. Gut 2009; 58: 929-39.

175. Choi EW, Shin IS, Park SY, Park JH, Kim JS, Yoon EJ, et al. Reversal of Serological, Immunological and Histological Dysfunction in Systemic Lupus Erythematosus Mice by Long-Term Serial Adipose Tissue-Derived Mesenchymal Stem Cell Transplantation. Arthritis Rheum 2012; 64: 243-53.

176. Yañez R, Lamana ML, García-Castro J, Colmenero I, Ramírez M, Bueren JA. Adipose Tissue-Derived Mesenchymal Stem Cells Have *In Vivo* Immunosupresive Properties Applicable for the Control of the Graft-Versus-Host Disease. Stem Cells 2006; 24: 2582-91.

177. Fang B, Song Y, Zhao RC, Han Q, Lin Q. Using Human Adipose Tissue-Derived Mesenchymal Stem Cells as Salvage Therapy for Hepatic Graft-Versus-Host Disease Resembling Acute Hepatitis. Transplant Proc 2007; 39: 1710-3.

178. Kang HM, Kim J, Park S, Kim J, Kim H, Kim KS, *et al*. Insulin-Secreting Cells from Human Eyelid-Derived Stem Cells Alleviate Type 1 Diabetes in Immunocompetent Mice. Stem Cells 2009; 27: 1999-2008.

179. Chandra V, Swetha G, Muthyala S, Jaiswal AK, Bellare JR, Nair PD, *et al*. Islet-Like Cell Agregates Generated from Human Adipose Tissue Derived Stem Cells Ameliorate Experimental Diabetes in Mice. PLoS One 2011; 6: E20615.

180. Lewis DS, Soderstrom PG. *In Vivo* and *In Vitro* Development of Visceral Adipose Tissue in a Nonhuman Primate (Papio species). Metabolism 1993; 42: 1277-83.

181. Zuk PA. Viral Transduction of Adipose-Derived Stem Cells. Methods Mol Biol 2011; 702: 345-57.